|
|
|
|
Gene Therapy - Studies from M.E. Kelly et al have provided new data on gene therapy
Learn more about a six-week, no-risk free trial of Virus Weekly We're a pay-per-view site for premium content.If you'd like to purchase this article, it's only $3.00. Gene Therapy Studies from M.E. Kelly et al have provided new data...
|
|
|
Hemophilia Research Award Received By Keri Smith, Ph.D., UT Scientist
Keri Smith, Ph.D., an assistant professor of pathology and laboratory medicine at The University of Texas Health Science Center at Houston, has received a Career Development Award from the National Hemophilia Foundation. The award...
|
|
|
Science fiction? Aerosol delivery of an engineered virus halts lung cancer progression in mice
Nasal sprays containing special viruses may revolutionize the field of pharmacology to correct a multitude of devastating genetic and sporadic human diseases including lung cancer.Lung cancer in conjunction with liver and pancreatic...
|
|
|
Wyeth, Catalyst Sign Agreement To Develop, Commercialize Factor VIIa Products
Wyeth to support the discovery, research and preclinical development Wyeth and Catalyst have entered into a collaboration for the discovery, development and commercialization of Factor VIIa products, to treat hemophilia and other...
|
|
|
WYETH PHARMACEUTICALS and CATALYST BIOSCIENCES announce agreement to develop and commercialize factor VIIa pro
Multi-Product Collaboration Valued Potentially at More Than $500 Million Collegeville, PA and South San Francisco, CA.- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Catalyst Biosciences, Inc.today announced that the two...
|
|
|
Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Pro
Multi-Product Collaboration Valued Potentially at More Than $500 Million COLLEGEVILLE, Pa., and SOUTH SAN FRANCISCO, Calif., June 30 (HSMN NewsFeed) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ) and Catalyst Biosciences, Inc.
|
|
|
Wyeth Pharmaceuticals signs agreement Catalyst Biosciences for Factor VIIa products
Wyeth Pharmaceuticals, a division of Wyeth, and Catalyst Biosciences, Inc.have formed an exclusive worldwide collaboration for the discovery, development, and commercialization of Factor VIIa products to treat hemophilia and other...
|
|
|
Wyeth and Catalyst Biosciences form collaboration for Factor VIIa products
(Datamonitor via COMTEX) -- WYE | Quote | Chart | News | PowerRating -- Wyeth Pharmaceuticals, a division of Wyeth, and Catalyst Biosciences, a biopharmaceutical company, have formed an exclusive worldwide collaboration for the discovery,...
|
|
|
WYETH PHARMACEUTICALS AND CATALYST BIOSCIENCES ANNOUNCE AGREEMENT TO DEVELOP AND COMMERCIALIZE FACTOR VIIa PRO
3652 live jobs on PharmiWeb.com now Multi-Product Collaboration Valued Potentially at More Than $500 Million Collegeville, PA and South San Francisco, CA, June 30, 2009 - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Catalyst...
|
|
|
Catalyst Biosciences Partners with Wyeth, Deal Could Be Worth $500 Million+
Catalyst Biosciences Inc., a South San Francisco-based developer of engineered proteases, has signed an exclusive worldwide collaboration agreement with Wyeth (NYSE: WYE), related to Factor VIIa products to treat hemophilia and other...
|
|
|
Wyeth Pharmaceuticals, Catalyst collaborating on hemophilia drug
Wyeth Pharmaceuticals said Tuesday that it has formed an exclusive worldwide collaboration with to develop treatments for hemophilia and other bleeding conditions.Collegeville, Pa.-based Wyeth Pharmaceuticals, a division of Wyeth ...
|
|
|
Wyeth Pharmaceuticals signs agreement Catalyst Biosciences for Factor VIIa products
(Datamonitor Financial Deals Tracker via COMTEX) -- WYE | Quote | Chart | News | PowerRating -- Wyeth Pharmaceuticals, a division of Wyeth, and Catalyst Biosciences, Inc.have formed an exclusive worldwide collaboration for the discovery,...
|
|
|
Wyeth, Catalyst sign deal worth $500mn
Wyeth Pharmaceuticals and Catalyst Biosciences have formed an exclusive worldwide collaboration for the discovery, development and commercialization of Factor VIIa products to treat hemophilia and other bleeding conditions.Total...
|
|
|
Cold Spring Harbor Lab eyes Sudoku in DNA research
(Newsday - McClatchy-Tribune Information Services via COMTEX) -- Sudoku, an 81-box numerical sequence puzzle, may be just a coffee-table conundrum to some, but for Cold Spring Harbor scientists it is the guide to hastening the way DNA is...
|
|
|
Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Pro
Multi-Product Collaboration Valued Potentially at More Than $500 Million COLLEGEVILLE, Pa.Through the collaboration, Wyeth will support the discovery, research and preclinical development by Catalyst of Factor VIIa products, including CB...
|
|
|
Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement
Wyeth Pharmaceuticals, a division of Wyeth and Catalyst Biosciences, Inc.today announced that the two companies have formed an exclusive worldwide collaboration for the discovery, development and commercialization of Factor VIIa products...
|
|
|
Wyeth, Catalyst announce collaboration for hemophilia drug
COLLEGEVILLE, Pa.(Jun. 30) Two drug companies will collaborate to develop treatments for hemophilia and other bleeding conditions using a blood coagulant. Wyeth and South San Francisco, Calif.-based Catalyst Biosciences...
|
|
|
Wyeth, Catalyst Enter Factor VIIa R&D Pact
Wyethand Catalyst Biosciences, Inc.have formed an exclusive worldwide collaboration for the discovery, development and commercialization of Factor VIIa products to treat hemophilia and other bleeding conditions. Total payments...
|
|
|
Wyeth Pharmaceuticals, Catalyst collaborating on hemophilia drug
Philadelphia Business Journal Related News Wyeth Pharmaceuticals said Tuesday that it has formed an exclusive worldwide collaboration with Catalyst Biosciences Inc.to develop treatments for hemophilia and other bleeding conditions....
|
|
|
Wyeth, Catalyst Biosciences Form Exclusive Worldwide Collaboration To Develop, Commercialize Factor VIIa Produ
AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Catalyst Biosciences, Inc.announced that along with Wyeth Pharmaceuticals, a division of Wyeth (WYE: News ), it formed an exclusive worldwide collaboration for the discovery, development and...
|
|
|
Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Pro
% Enter Symbols: Sponsored by: Multi-Product Collaboration Valued Potentially at More Than $500 Million COLLEGEVILLE, Pa., and SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth and Catalyst...
|
|
|
Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Pro
COLLEGEVILLE, Pa., and SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE) and Catalyst Biosciences, Inc.today announced that the two companies have formed an exclusive worldwide...
|
|
|
Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Pro
Multi-Product Collaboration Valued Potentially at More Than $500 Million COLLEGEVILLE, Pa., and SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Catalyst Biosciences, Inc.
|
|
|
Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Pro
Multi-Product Collaboration Valued Potentially at More Than $500 Million COLLEGEVILLE, Pa., and SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Catalyst Biosciences, Inc.
|
|
|
Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Pro
Multi-Product Collaboration Valued Potentially at More Than $500 Million COLLEGEVILLE, Pa., and SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Catalyst Biosciences, Inc.
|
